Literature DB >> 10850310

Rituximab immunotherapy for non-Hodgkin's lymphoma.

C A White1.   

Abstract

Rituximab, a chimeric monoclonal antibody targeting the CD20 antigen on B lymphocytes, is now the standard treatment for relapsed, low-grade or follicular non-Hodgkin's lymphoma.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10850310     DOI： 10.1089/cbr.1999.14.241

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN： 1084-9785            Impact factor:   3.099


  2 in total

1.  Structure-activity relationships between the Aconitum C20-diterpenoid alkaloid derivatives and the growth suppressive activities of Non-Hodgkin's lymphoma Raji cells and human hematopoietic stem/progenitor cells.

Authors:  Masaharu Hazawa; Kenji Takahashi; Koji Wada; Takao Mori; Norio Kawahara; Ikuo Kashiwakura
Journal:  Invest New Drugs       Date:  2009-09-26       Impact factor: 3.850

2.  The Antimicrobial Peptide, Nisin, Synergistically Enhances the Cytotoxic and Apoptotic Effects of Rituximab Treatment on Human Burkitt's Lymphoma Cell Lines.

Authors:  Pantea Mohammadi; Mina Zangeneh; Hamid-Reza Mohammadi-Motlagh; Fatemeh Khademi
Journal:  Rep Biochem Mol Biol       Date:  2020-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.